405 related articles for article (PubMed ID: 25393310)
1. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
2. Claudin expression in breast cancer: high or low, what to expect?
Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.
Katayama A; Handa T; Komatsu K; Togo M; Horiguchi J; Nishiyama M; Oyama T
Pathol Int; 2017 Aug; 67(8):404-413. PubMed ID: 28699235
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of claudins -1 and -4 in oral squamous cell carcinoma.
DE Vicente JC; Fernández-Valle Á; Vivanco-Allende B; Santamarta TR; Lequerica-Fernández P; Hernández-Vallejo G; Allonca-Campa E
Anticancer Res; 2015 May; 35(5):2949-59. PubMed ID: 25964581
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
6. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
[TBL] [Abstract][Full Text] [Related]
7. Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases.
Moldvay J; Fábián K; Jäckel M; Németh Z; Bogos K; Furák J; Tiszlavicz L; Fillinger J; Döme B; Schaff Z
Pathol Oncol Res; 2017 Jan; 23(1):151-156. PubMed ID: 27687058
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of claudin-1 correlates with recurrence status in breast cancer.
Morohashi S; Kusumi T; Sato F; Odagiri H; Chiba H; Yoshihara S; Hakamada K; Sasaki M; Kijima H
Int J Mol Med; 2007 Aug; 20(2):139-43. PubMed ID: 17611630
[TBL] [Abstract][Full Text] [Related]
10. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
11. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P
BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498
[TBL] [Abstract][Full Text] [Related]
12. Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma.
Zhou S; Piao X; Wang C; Wang R; Song Z
Mol Med Rep; 2019 Jul; 20(1):393-400. PubMed ID: 31115553
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in
Hu A; Li J; Ruan S; Fan Y; Liao Y
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910845
[No Abstract] [Full Text] [Related]
15. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
16. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
17. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
18. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the CLDN1 and CLDN7 genes are related to differentiation and tumor stage in colon carcinoma.
Hahn-Strömberg V; Askari S; Befekadu R; Matthiessen P; Karlsson S; Nilsson TK
APMIS; 2014 Jul; 122(7):636-42. PubMed ID: 24479816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
